~~<i id='7FA6A1FDA4'><strike id='7FA6A1FDA4'><tt id='7FA6A1FDA4'><pre id='7FA6A1FDA4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

leisure time

author：leisure time 2025-09-30 17:46:16 - browse：94

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

explore

hotspot

leisure time

AliKhodadoust,anophthalmologistinConnecticut,earnedaplaceinmedicalhistoryafterhaving100millionviruse

WSS

When women are denied an abortion, their children fare worse than peers

Senators push IRS to launch nonprofit hospital probe

What to know about the judge who will handle the Trump case

Patients, digital health players weigh in on FTC's data privacy plan

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Senators push IRS to launch nonprofit hospital probe

Wikipedia

leisure time

explore

Sports medicine is finally prioritizing gender equality

Bird flu researchers hone in on Finland’s mink farms

Malaria cases in Florida and Texas: Here’s what you need to know

Liquid biopsy for lung cancer is launched by Delfi

As demand for Covid shots wanes, Moderna seeks its next success

Why Charlie Gard's case is so disturbing to Americans

Apple is now the first public company to be valued at $3 trillion

FDA authorizes Novavax’s updated Covid

In age of alternative facts, a scholarly course on calling out crap

YouTube cracks down on misinformation on cancer treatment

explore

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

A virus, fished out of a lake, may have saved a man’s life

Illinois Supreme Court finds assault weapons ban constitutional

Illumina slashes 2023 revenue projections yet again

Hospitals are dialing back on venture capital investing

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

hotspot

hotspot

leisure time